WO2001036432A3 - 18 human secreted proteins - Google Patents

18 human secreted proteins Download PDF

Info

Publication number
WO2001036432A3
WO2001036432A3 PCT/US2000/031162 US0031162W WO0136432A3 WO 2001036432 A3 WO2001036432 A3 WO 2001036432A3 US 0031162 W US0031162 W US 0031162W WO 0136432 A3 WO0136432 A3 WO 0136432A3
Authority
WO
WIPO (PCT)
Prior art keywords
secreted proteins
human secreted
proteins
novel human
relates
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2000/031162
Other languages
French (fr)
Other versions
WO2001036432A2 (en
Inventor
Steven M Ruben
George A Komatsoulis
Kevin P Baker
Paul E Young
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Human Genome Sciences Inc
Original Assignee
Human Genome Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Human Genome Sciences Inc filed Critical Human Genome Sciences Inc
Priority to JP2001538921A priority Critical patent/JP2003514541A/en
Priority to AU16044/01A priority patent/AU1604401A/en
Priority to EP00978592A priority patent/EP1234030A4/en
Priority to CA002388777A priority patent/CA2388777A1/en
Publication of WO2001036432A2 publication Critical patent/WO2001036432A2/en
Publication of WO2001036432A3 publication Critical patent/WO2001036432A3/en
Anticipated expiration legal-status Critical
Priority to US12/198,817 priority patent/US7968689B2/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating diseases, disorders, and/or conditions related to these novel human secreted proteins.
PCT/US2000/031162 1997-03-07 2000-11-15 18 human secreted proteins Ceased WO2001036432A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
JP2001538921A JP2003514541A (en) 1999-11-19 2000-11-15 18 human secreted proteins
AU16044/01A AU1604401A (en) 1999-11-19 2000-11-15 18 human secreted proteins
EP00978592A EP1234030A4 (en) 1999-11-19 2000-11-15 18 HUMAN SECRETED PROTEINS
CA002388777A CA2388777A1 (en) 1999-11-19 2000-11-15 18 human secreted proteins
US12/198,817 US7968689B2 (en) 1997-03-07 2008-08-26 Antibodies to HSDEK49 polypeptides

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US16641599P 1999-11-19 1999-11-19
US60/166,415 1999-11-19
US21513600P 2000-06-30 2000-06-30
US60/215,136 2000-06-30

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/031282 Continuation-In-Part WO2001036440A1 (en) 1997-03-07 2000-11-15 23 human secreted proteins

Related Child Applications (2)

Application Number Title Priority Date Filing Date
PCT/US2000/030674 Continuation-In-Part WO2001034800A1 (en) 1997-03-07 2000-11-08 19 human secreted proteins
US10/100,683 Continuation-In-Part US7368531B2 (en) 1997-03-07 2002-03-19 Human secreted proteins

Publications (2)

Publication Number Publication Date
WO2001036432A2 WO2001036432A2 (en) 2001-05-25
WO2001036432A3 true WO2001036432A3 (en) 2002-05-10

Family

ID=26862246

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/031162 Ceased WO2001036432A2 (en) 1997-03-07 2000-11-15 18 human secreted proteins

Country Status (5)

Country Link
EP (1) EP1234030A4 (en)
JP (1) JP2003514541A (en)
AU (1) AU1604401A (en)
CA (1) CA2388777A1 (en)
WO (1) WO2001036432A2 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8877462B2 (en) 2000-06-28 2014-11-04 Glycofi, Inc. Combinatorial DNA library for producing modified N-glycans in lower eukaryotes
US8986949B2 (en) 2003-02-20 2015-03-24 Glycofi, Inc. Endomannosidases in the modification of glycoproteins in eukaryotes

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7192589B2 (en) * 1998-09-16 2007-03-20 Genentech, Inc. Treatment of inflammatory disorders with STIgMA immunoadhesins
US7419663B2 (en) 1998-03-20 2008-09-02 Genentech, Inc. Treatment of complement-associated disorders
US8088386B2 (en) 1998-03-20 2012-01-03 Genentech, Inc. Treatment of complement-associated disorders
US8007798B2 (en) 1997-11-21 2011-08-30 Genentech, Inc. Treatment of complement-associated disorders
US7598055B2 (en) 2000-06-28 2009-10-06 Glycofi, Inc. N-acetylglucosaminyltransferase III expression in lower eukaryotes
US7625756B2 (en) 2000-06-28 2009-12-01 GycoFi, Inc. Expression of class 2 mannosidase and class III mannosidase in lower eukaryotic cells
EP2322644A1 (en) 2000-06-28 2011-05-18 GlycoFi, Inc. Methods for producing modified glycoproteins
KR20030029847A (en) * 2000-08-24 2003-04-16 제넨테크, 인크. Compositions and methods for the diagnosis and treatment of tumor
WO2004022594A2 (en) * 2002-09-06 2004-03-18 Cytos Biotechnology Ag Immune modulatory compounds and methods
JP4897690B2 (en) * 2004-10-12 2012-03-14 ジェネンテック， インコーポレイテッド CRIg polypeptide for prevention and treatment of complement related disorders
EP3299027A1 (en) 2005-11-04 2018-03-28 Genentech, Inc. Use of complement pathway inhibitors to treat ocular diseases
US7776573B2 (en) 2006-06-01 2010-08-17 Genentech, Inc. Crystal structure of CRIg and C3b:CRIg complex
CN106188303A (en) 2006-11-02 2016-12-07 健泰科生物技术公司 Humanized anti-D factor antibody
AR066660A1 (en) 2007-05-23 2009-09-02 Genentech Inc PREVENTION AND TREATMENT OF EYE CONDITIONS ASSOCIATED WITH THEIR COMPLEMENT
CR20170001A (en) 2008-04-28 2017-08-10 Genentech Inc ANTI FACTOR D HUMANIZED ANTIBODIES
RU2553517C2 (en) 2008-05-06 2015-06-20 Дженентек, Инк. Affinity-matured crig versions
KR101137019B1 (en) 2009-05-25 2012-05-24 한국생명공학연구원 A novel g protein coupled receptor and a use thereof
US20130101590A1 (en) 2010-04-09 2013-04-25 Heather A. Arnett Btnl9 proteins, nucleic acids, and antibodies and uses thereof
AU2014306867B2 (en) 2013-08-12 2017-10-26 Genentech, Inc. Compositions and method for treating complement-associated conditions
EP3137503A1 (en) 2014-05-01 2017-03-08 Genentech, Inc. Anti-factor d antibody variants and uses thereof
WO2017075252A1 (en) 2015-10-30 2017-05-04 Genentech, Inc. Anti-factor d antibody variant conjugates and uses thereof
US10407510B2 (en) 2015-10-30 2019-09-10 Genentech, Inc. Anti-factor D antibodies and conjugates
WO2017150681A1 (en) * 2016-03-03 2017-09-08 東亞合成株式会社 Amyotrophic lateral sclerosis diagnostic method using signal peptide as index

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999001550A1 (en) * 1997-07-03 1999-01-14 Dana-Farber Cancer Institute A method for detection of alterations in msh5
WO1999057261A2 (en) * 1998-04-30 1999-11-11 Hoechst Marion Roussel Human bmp-2 promoter and method for exploring bone-related substance by using the same

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1224281A4 (en) * 1999-09-27 2003-10-15 Human Genome Sciences Inc 37 HUMAN SECRETED PROTEINS

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999001550A1 (en) * 1997-07-03 1999-01-14 Dana-Farber Cancer Institute A method for detection of alterations in msh5
WO1999057261A2 (en) * 1998-04-30 1999-11-11 Hoechst Marion Roussel Human bmp-2 promoter and method for exploring bone-related substance by using the same

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP1234030A4 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8877462B2 (en) 2000-06-28 2014-11-04 Glycofi, Inc. Combinatorial DNA library for producing modified N-glycans in lower eukaryotes
US8883483B2 (en) 2000-06-28 2014-11-11 Glycofi, Inc. Combinatorial DNA library for producing modified N-glycans in lower eukaryotes
US8986949B2 (en) 2003-02-20 2015-03-24 Glycofi, Inc. Endomannosidases in the modification of glycoproteins in eukaryotes

Also Published As

Publication number Publication date
EP1234030A4 (en) 2003-05-07
CA2388777A1 (en) 2001-05-25
AU1604401A (en) 2001-05-30
WO2001036432A2 (en) 2001-05-25
JP2003514541A (en) 2003-04-22
EP1234030A2 (en) 2002-08-28

Similar Documents

Publication Publication Date Title
WO1998039446A3 (en) 70 human secreted proteins
WO1998039448A3 (en) 186 human secreted proteins
WO1998040483A3 (en) 28 human secreted proteins
WO1998031800A3 (en) Human proteins
EP1053245A4 (en) 45 HUMAN SECRETED PROTEINS
WO2001032910A3 (en) 27 human secreted proteins
WO2001036432A3 (en) 18 human secreted proteins
WO1998045712A3 (en) 20 human secreted proteins
CY1111950T1 (en) 32 HUMAN EXTRACTED PROTEINS
WO2001012776A3 (en) 18 human secreted proteins
WO2001034768A3 (en) 15 human secreted proteins
WO2000077026A8 (en) 49 human secreted proteins
WO2000017222A8 (en) 31 human secreted proteins
WO2000052136A3 (en) Human glycosylation enzymes
WO2000063230A3 (en) 49 human secreted proteins
WO2001062891A3 (en) 207 human secreted proteins
WO2000073323A3 (en) Adam polynucleotides and polypeptides
EP1042342A4 (en) 53 HUMAN SECRETED PROTEINS
WO2001012775A8 (en) 25 human secreted proteins
WO2000058339A3 (en) 50 human secreted proteins
WO2000061624A8 (en) 48 human secreted proteins
WO2000043495A3 (en) 33 human secreted proteins
WO2000061596A8 (en) 50 human secreted proteins
WO2003052377A9 (en) 41 human secreted proteins
WO2001034769A3 (en) 24 human secreted proteins

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2388777

Country of ref document: CA

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2001 538921

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 2000978592

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2000978592

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 2000978592

Country of ref document: EP